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Background:  BRCA1 methylation has been associated with homologous recombination 
deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated 
tubal/ovarian cancer (OC) do not consistently support improved survival following platinum 
chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of 
individual participant data. 
Methods: 2636 participants’ data across 15 studies was analysed. BRCA1-methylated tumors 
were defined according to their original study. Associations between BRCA1 methylation and 
clinico-pathological characteristics were evaluated. The effects of methylation on overall survival 
(OS) and progression-free survival (PFS) were examined using mixed-effects models. All 
statistical tests were two-sided. 
Results: 430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated 
with younger age and advanced-stage high-grade serous OC. There were no survival 
differences between BRCA1-methylated and non-BRCA1-methylated OC (median PFS 20 vs 
18.5 months, HR 1.01, 95% CI [0.87–1.16], P=0.98; median OS 46.6 vs 48 months, HR 1.02, 
95% CI [0.87–1.18], P=0.96). Where BRCA1/2 mutations were evaluated (n=1248), BRCA1 
methylation displayed no survival advantage over BRCA1/2 intact (BRCA1/2 wild type non-
BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation.  Where 
BRCA1 methylation was determined using methylation-specific PCR and gel electrophoresis 
(n=834), it was associated with improved survival (PFS: HR 0.80, 95% CI [0.66–0.97], P=0.02; 
OS: HR 0.80, 95% CI [0.63–1.00], P=0.05) on mixed-effects modelling. 
Conclusion: BRCA1-methylated OC displays similar clinico-pathological features to BRCA1-
mutated OC, but does not impact survival. Heterogeneity within BRCA1 methylation assays 
influences survival associations. Refining these assays may better identify cases with 
























Epithelial tubal, primary peritoneal and ovarian cancer, hereafter referred to as ovarian cancer 
(OC), is an aggressive disease with poor patient outcomes. High-grade serous cancer (HGSC) 
is the most common and lethal form of OC1. Targeting homologous recombination deficiency 
(HRD), a molecular hallmark in approximately 50% of HGSC, could improve outcomes for a 
significant number of women with OC. BRCA1/2 germline and somatic mutations are observed 
in 15-20% of OC and account for ~1/3 of HRD tumors2,3. These mutations are predictors of 
platinum and poly-ADP-ribose polymerase inhibitors (PARPi) response and are prognostic for 
improved outcomes in OC4,5. Identifying other mechanisms producing HRD could expand the 
number of women with OC benefiting from PARPi. Another possible though less well 
characterised mechanism of HRD is BRCA1 promoter methylation, occurring in approximately 
10-15% of HGSC3,6-8, although reported rates vary between 5-89.9%9,10. By virtue of epigenetic 
silencing of BRCA1, BRCA1-methylated OC is postulated to compare to BRCA1-mutated OC in 
terms of HRD, platinum chemotherapy and PARPi sensitivity, clinical characteristics and 
survival outcomes.  
Cell line models of BRCA1-methylated OC display specific sensitivity to platinum chemotherapy 
and PARPi11. Analysis of BRCA1-methylated OC specimens, albeit in small cohorts, 
consistently display low BRCA1 protein and mRNA expression7,12-14. In the clinical setting, few 
retrospective studies have addressed the implication of BRCA1 methylation on clinical 
characteristics and patient outcomes after platinum chemotherapy in OC, with inconsistent 
results. Recent large studies utilizing genome wide methylation arrays (GWMA) correlated to 
BRCA1 mRNA expression to detect BRCA1 methylation demonstrate no prognostic impact on 
survival3,15. One study, however, shows similar hazard ratios for overall survival (OS) for both 
BRCA1-methylated (HR 0.74, 95% CI [0.49 – 1.14]) and BRCA1-mutated OC (HR 0.75, 95% CI 
[0.46 – 1.22])15 as compared to BRCA1/2 intact disease, though neither was statistically 
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significant. In contrast, smaller studies (n=27 to 332) utilizing methylation sensitive or 
methylation specific PCR (MSP) as a diagnostic assay have conflicting findings with regards to 
associations with platinum sensitivity and survival. While some report statistically significant 
improvements in survival16,17, as compared to non-BRCA1-methylated OC, others observe 
trends towards a worse outcome18. A comprehensive study of the clinical implications of 
BRCA1-methylated OC is required.  
 
METHODS 
Search strategy and study selection 
The conduct of this meta-analysis followed the Meta-Analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines. Original investigations were sought in PUBMED/Medline 
through 1 April 2018, with no restrictions on publication date or language. The search strategy 
followed the syntax: (BRCA*[Title/Abstract] OR BRCA1*[Title/Abstract]) AND 
methylat*[Title/Abstract] AND ovar*[Title/Abstract], and was performed independently by two 
investigators (R.K. and B.S.), who independently reviewed abstracts for eligibility. Additionally, 
abstracts from the 2009-2018 ASCO, ESMO and SGO annual meetings were searched. Eligible 
articles’ reference lists were reviewed for further potential studies. The inclusion of published 
and unpublished studies regardless of publication language or date attempts to minimize 
publication bias. 
Eligible studies needed to: 1) assess BRCA1 methylation in fallopian tube, primary peritoneal or 
ovarian cancer specimens 2) report on participant and disease characteristics 3) report on 
progression-free survival (PFS) and/or OS 4) provide suitable methodology on their BRCA1 
methylation assay. Clinical trials involving PARPi were not eligible. There were no restrictions 
on the BRCA1 methylation assay used. As BRCA2 methylation seldom occurs in ovarian 
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cancer, we did not investigate its role in OC. Studies reporting solely on BRCA2 methylation in 
OC were therefore excluded. 
Data acquisition 
The following anonymized individual participant data (IPD) was requested from eligible studies’ 
authors, using a pre-specified template and coding: 1) BRCA1 methylation assay details, 2) 
participant and disease characteristics (age, histology, FIGO stage19, grade, HRD score, 
BRCA1 methylation, BRCA1/2 mutation), 3) treatment details (receipt of adjuvant/neoadjuvant 
platinum chemotherapy, degree of surgical cytoreduction, platinum sensitivity) and 4) survival 
outcomes (platinum-free interval (PFI), PFS and OS). Tumor HRD score is the unweighted sum 
of loss of heterozygosity (LOH), telomeric allelic imbalance, and large-scale state transitions20. 
A score ≥ 42 defines a tumor as HR deficient21. 
Data integrity and risk of bias assessment 
IPD was checked for errors, missing data, and consistency with study publications. Study 
authors were contacted to resolve discrepancies or obtain missing data. Studies with partially 
missing data were analysed on the basis of available data. 
Bias assessment for studies’ internal validity was performed using the ROBINS-I tool22 
recommended by the Cochrane collaboration for non-randomized studies.  
Statistical analysis 
This meta-analysis aims to clinically characterize BRCA1-methylated OC. Its primary and 
secondary objectives were to determine the clinico-pathological characteristics associated with 
BRCA1 methylation and ascertain the prognostic impact of BRCA1 methylation on PFS and OS, 
respectively, in OC. A tumor was considered BRCA1-methylated if it was defined as such within 
its original study. OS was the time from diagnosis until death; participants were censored at the 
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last known survival date. PFS was the time from diagnosis until CA125 and/or RECIST disease 
progression, or death, whichever occurred first; participants were censored at the last known 
progression-free date. 
Descriptive statistics were calculated for the combined IPD to summarize participants and 
disease characteristics for BRCA1-methylated OC versus non-BRCA1-methylated OC. The 
characteristics of interest were age, histotype, stage, grade, residual disease after surgical 
cytoreduction and platinum sensitivity. Comparisons between BRCA1-methylated and non-
BRCA1-methylated OC were made using the generalized Cochran-Mantel-Haenzel test for 
repeated tests of independence with continuity correction to facilitate combining the multiple 
cohorts. Where available, HRD scores of BRCA1-methylated OC were compared to BRCA1/2 
intact, BRCA1-mutated and BRCA2-mutated OC using unpaired t-tests. The Kaplan Meier 
method (logrank test) was used to generate survival plots via the R package survival23. Forest 
plots were generated using the R package survcomp24. Univariate and multivariate analysis of 
PFS and OS were performed using Cox proportional hazards regression models, which 
estimated hazard ratios (HR) and 95% confidence intervals (CI) for each individual datasets. A 
mixed effects cox model was then used to perform univariate and multivariate analysis of the 
combined dataset, comparing BRCA1-methylated OC to non-BRCA1 methylated OC. These 
models were generated using the R packages survival and coxme25 respectively. Multivariate 
models were adjusted for the following clinical variables: age, grade, stage, residual disease 
after surgical cytoreduction. For cohorts with available germline and/or somatic BRCA1/2 
mutation data, the above analyses were repeated comparing BRCA1-methylated to BRCA1/2 
intact (BRCA1/2-wild type non-BRCA1-methylated) OC, in order to eliminate the potential 
survival bias attributed by BRCA1/2-mutated OC in the non-BRCA1-methylated population. P-
values were adjusted for multiple testing (Benjamini-Hochberg method26). Heterogeneity was 
quantified using the I2 statistic27, which provides a numerical value ranging between 0% - 100%. 
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This value and its 95% confidence interval were interpreted according to ranges described in 
the Cochrane Handbook for Systematic Review of Interventions, with values between 0 – 40%, 
30 – 60%, 50 – 90% and 75 – 100% suggesting low, moderate, considerable and substantial 
heterogeneity, respectively28. For all analyses, P values less than 0.05 (two-tailed) were 
considered statistically significant. All calculations were performed in the R statistical 




The literature search retrieved 159 records (Figure 1). Three were duplicated datasets, 8 were 
conference abstracts identified in the Pubmed search, 90 were irrelevant, 21 were reviews, 13 
had no survival data, 1 had unsatisfactory methodology details, 1 concerned a PARPi clinical 
trial and 22 were eligible. Following contact with authors of eligible studies, 5 did not participate 
and 4 could not access or share the data (Table S1)14,17,18,29-34. In addition, we accessed 2 
unpublished cohorts. One author provided data on additional patients not included in the original 
publication. Overall, 15 observational studies (430 cases; 2206 controls) were included3,13,15,16,35-
43(Tables S2A-S2C). 
Quality assessment 
Individual study assessments were made on the basis of raw IPD, study manuscript and any 
necessary clarifications with study authors (Table S3).  Studies’ internal validity was deemed 
overall good, with a likely low risk of bias on the meta-analysis results. Of the 15 studies, 13 had 
an overall moderate risk of bias, mainly owing to the potential for confounding baseline factors 
that were nevertheless adjusted for appropriately. In addition, 4 studies had a moderate risk in 
patient selection with regards to determining the clinicopathological characteristics of BRCA1-
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methylated OC, as only HGSC were included. A moderate risk was also found for 5 studies 
where intended BRCA1 methylation assessment failed due to inadequate tumor tissue/DNA. 
Two studies had an overall serious risk of bias, owing to missing data. One did not collect tumor 
grade and OS data for their entire cohort (n=35)39. The other provided IPD for 61.0% 
(n=147/241) of study participants due to time constraints in data collection and provision36. 
Neither of these two studies collected data pertaining to BRCA1/2 mutation status or HRD 
score. The exclusion of these two studies from the entire meta-analysis cohort did not alter the 
results of the meta-analysis for any of the endpoints measured (data not shown). It was 
therefore deemed reasonable to include these two studies in this meta-analysis of individual 
patient data. 
Participant characteristics  
Data was obtained on 2645 participants. 9 participants with dual aberrations (BRCA1 
methylation and/or BRCA1/2 mutations) were excluded (Table S2), leaving 2636 participants 
within the analysis. Amongst participants with known BRCA1/2 mutation status (n=1257), 
BRCA1 methylation and BRCA1 mutation were mutually exclusive (odds ratio: 0.18, P=0.003), 
as were BRCA1 methylation and BRCA2 mutation (odds ratio 0.33, P=0.04). In the entire 
cohort, the median age was 59 years old. Fallopian tube and primary peritoneal cancers 
comprised 0.35% (n=7/2022) and 1.3% (n=26/2022) of the entire cohort, respectively. 85.4% 
(n=2247/2630) participants presented with advanced stage disease (FIGO Stage III/IV). 95.6% 
(n=2396/2506) participants received (neo)adjuvant platinum-based therapy. 79.7% 
(n=2065/2592) were HGSC. Stage III/IV HGSC comprised 73.9% participants (n=1904/2576).  
Surgical cytoreduction below 1 cm residual disease was achieved in 71.9% (n=1757/2444) 
participants (Table S4). 




The BRCA1 methylation rate varied in studies from 6.2% to 73.7% (Table S2A), with a pooled 
rate of 16.3% (n=430/2636). BRCA1-methylated OC was significantly associated with younger 
age (P=0.005), and high grade disease (P=0.03) (Table 1). No other statistically significant 
clinico-pathological correlations were observed.  
 
Germline and/or somatic BRCA1/2 mutation status was available for 1248 participants from 7/15 
included studies. Of these, 10.6% (n=132/1248) were BRCA1-mutated, 6.5% (n=81/1248) were 
BRCA2-mutated and 10.3% (n=128/1248) were BRCA1-methylated. Within this cohort with 
known germline and/or somatic BRCA1/2 mutation status, BRCA1 methylation was also 
associated with younger age (P=0.007) and high grade disease (P=0.005), when compared to 
patients with BRCA1/2 intact OC. Furthermore, BRCA1-methylated OC was associated with 
advanced stage (P=0.01) and serous histology (P=0.009), compared to BRCA1/2 intact OC. 
BRCA1 mutation was associated with younger age (P<0.001), high grade (P=0.006), serous 
histology (P=0.005), advanced stage (P=0.02) and platinum sensitivity (P=0.008), when 
compared to BRCA1/2 intact disease. The clinico-pathological profile of BRCA1-methylated OC 
did not differ significantly from that of BRCA1-mutated OC (Table S5). 
 
Tumor HRD score was available for 447 participants (MDACC 2010 and TCGA 2011 cohorts). 
HRD scores were statistically significantly higher in BRCA1-methylated OC (median 68, 
interquartile range (IQR) 62- 74), compared to BRCA1/2 intact disease (median 26, IQR 18- 
38.8), BRCA1-mutated (median 63, IQR 56- 70) and BRCA2-mutated (median 56, IQR 44.5- 
65.5) disease (Figure 2). 
 
Association of BRCA1 methylation with survival 
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The median follow-up time was 2.8 years (range 0-18.3; IQR 1.5-4.8). There was a statistically 
significant constituent study effect on the cox regression model first used to associate BRCA1 
methylation with PFS and OS (P=1.17x10-13 and P=2.33x10-4, respectively). Statistically 
significant moderate to substantial heterogeneity was observed between studies for PFS (I2 = 
62% (CI 26%-86%), Q= 36.4, df=14, P<0.001). While not statistically significant, we note low 
heterogeneity between studies for the assessment of OS (I2= 37% (CI 0%-75%), Q=20.7, df=13, 
P=0.08), though the 95% confidence interval is wide. Clinically, heterogeneity is expected given 
observed differences between cohorts with regards to patient/disease clinical characteristics 
and study characteristics. A mixed-effect model was therefore employed to adjust for study 
heterogeneity. In order to justify our acceptance of the null hypothesis of this meta-analysis, we 
performed a power calculation utilizing observed information (study heterogeneity) and 
assumptions (predicted effect size). Using this information, we calculated that we have an 84% 
power to detect a modest effect size (cohan's d of 0.2), across the 15 studies with an average 
BRCA1 methylation rate of 29 samples per study and an average non-BRCA1 methylation rate 
of 147 samples per study with an alpha value of 0.05 and a moderate level of heterogeneity. 
In the combined population, there was no statistically significant difference in PFS and OS 
between BRCA1-methylated and non-BRCA1-methylated OC (median PFS 20 vs 18.5 months, 
HR 1.01, 95% CI[0.87-1.16], P=0.98; median OS 46.6 vs 48 months, HR 1.02, 95% CI[0.87-
1.18], P=0.96, respectively). This lack of association persisted in a multivariate model adjusted 
for age, stage, grade and cytoreduction (Figures 3-4A).  
 
Within the subgroup with known BRCA1/2 mutation status, BRCA1-methylated OC was 
associated with a worse PFS than BRCA1/2 intact OC on univariate analysis (median PFS 15.7 
vs 18 months, HR 1.26, 95% CI[1.02-1.56], P=0.03), though this significance was lost on 
multivariate analysis. There was no OS difference on univariate or multivariate analyses 
between the BRCA1-methylated and the BRCA1/2 intact groups (median OS 43.5 vs 47.5 
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months, univariate HR 1.05, 95% CI[0.83-1.32], P=0.70). BRCA1-mutated OC was only 
associated with a statistically significant improvement in PFS and OS, as compared to BRCA1/2 
intact OC, on multivariate analysis (PFS: median 17.3, univariate HR 0.94, 95% CI[0.75-1.17], 
P=0.57; multivariate HR 0.78, 95% CI[0.62-0.99], P=0.04; OS: median 47.4 months, univariate 
HR 0.81, 95% CI[0.64-1.03], P=0.09; multivariate HR 0.76, 95% CI[0.58-0.98], P=0.03). BRCA2 
mutation conferred a clear PFS and OS benefit compared to BRCA1/2 intact OC on univariate 
and multivariate analyses (median PFS: 28.6 months, univariate HR 0.58, 95% CI [0.44-0.78], 
P<0.001; median OS 87 months, univariate HR 0.55, 95% CI [0.40-0.77], P< 0.001) (Figure 4B, 
Table S5). 
 
Exploratory analysis of methylation methodology on survival 
We explored PFS and OS comparing BRCA1-methylated OC to non-BRCA1-methylated OC 
within 3 subgroups of the meta-analysis’ entire cohort divided according to methylation assay 
type: those studies utilising methylation-specific PCR (MSP) with gel electrophoresis (GE) (7 
studies, n=765), those utilising quantitative analysis of MSP or methylation sensitive restriction 
endonuclease digestion (MRED; 5 studies, n=828), and those utilising genome wide methylation 
arrays (GWMA; 3 studies, n=1043).  Methylation assays are further detailed in Table S2A and 
Figure S2S1. In the combined cohorts utilising MSP-GE, BRCA1-methylated OC was 
associated with an improved PFS and OS (univariate HR 0.80, 95% CI[0.66-0.97], P=0.02; 
univariate HR 0.80, 95% CI[0.63-1.00], P=0.05, respectively) as compared to non-BRCA1-
methylated OC, though statistical significance was lost for OS on multivariate analysis (P=0.08). 
Amongst cohorts utilising MSP/MRED with quantitative analysis, BRCA1-methylated OC was 
associated with a worse PFS (HR 1.47, 95%CI [1.10-1.96], P=0.008) and OS (HR 1.45, 
95%CI[1.05-2.00], P=0.02), when compared to non-BRCA1-methylated OC. This which 
persisted on multivariate analysis. There were no survival differences observed between 
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BRCA1-methylated OC and non-BRCA1-methylated OC in the subgroup employing GWMA 
(Figure 5, Table 3). 
 
DISCUSSION 
Dysfunctional BRCA1 and BRCA2 proteins as a result of BRCA1/2 mutations render OC 
particularly susceptible to therapies targeting the homologous recombination DNA repair 
pathway. While the association of BRCA1/2-mutated OC with improved survival resulting from 
sensitivity to (neo)adjuvant platinum-based chemotherapy is well established, the clinical and 
therapeutic implications of other BRCA1 dysfunction mechanisms is less understood. In a 
recent meta-analysis, loss of BRCA1 expression by immunohistochemistry was also associated 
with a statistically significant improved survival44, although the mechanisms behind absent 
BRCA1 protein expression were not specified. Gene silencing through promoter methylation is 
one such mechanism, though other potential indirect or post translational mechanisms leading 
to BRCA1 inactivation or reduced expression require investigation. Whilst BRCA1 methylation is 
a recognized event in OC, promoter methylation of BRCA2 appears to be a rare occurrence in 
OC, if at all. Amongst 6 studies investigating BRCA2 methylation in OC15,45-49, only 2 BRCA2-
methylated cases were identified amongst 612 cases tested. This meta-analysis was therefore 
limited to studies investigating BRCA1 methylation. Reports on BRCA1-methylated OC have 
been conflicting in terms of clinico-pathological associations, with smaller cohorts observing 
associations with FIGO stage I/II disease31 or a lack of association with any histotype18. Other 
cohorts limited their assessment of BRCA1 methylation to homogeneous HGSC cohorts, 
thereby precluding the detection of histopathological associations. Our study population 
comprised heterogeneous OC subtypes, though dominated by advanced stage HGSC. We 
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show that features of BRCA1-methylated OC mirror that of BRCA1-mutated disease in terms of 
advanced stage, high grade, serous disease, and a younger age at diagnosis. 
The expectation is therefore that BRCA1-methylated disease will be sensitive to platinum and 
PARPi by virtue of HRD. We provide evidence of HRD in BRCA1-methylated OC, as defined by 
the HRD score, albeit in a limited subgroup of participants derived from 2 studies. Cell line and 
patient-derived xenograft models of BRCA1-methylated OC demonstrate clear sensitivity to 
platinum and/or PARPi therapy11,50,51. Recent data from the ARIEL2 phase II clinical trial 
demonstrate an encouraging 63% (n=12/19) RECIST response rate amongst BRCA1-
methylated recurrent HGSC to the PARPi rucaparib, as compared to response rates of 79% 
(n=23/29) and 13.5% (n=7/52) observed in BRCA1-mutated and BRCA1 intact/low genome-
wide LOH recurrent HGSC, respectively52. However, large clinical cohorts (e.g. TCGA) show no 
difference in PFI by BRCA1 methylation status. Within this meta-analysis, PFI data was 
unavailable for 56.9% (n=1539/2636) of participants, thereby precluding a representative 
assessment. Nevertheless, we found no association between BRCA1-methylated OC and 
platinum sensitivity. Moreover, we observed no PFS difference between BRCA1-methylated and 
non-BRCA1-methylated OC in the entire cohort. When evaluated against the more appropriate 
comparator population that is BRCA1/2 intact OC, albeit within a smaller cohort of 1248 
patients, BRCA1-methylated OC once again did not display improved survival. In contrast, both 
BRCA1 and BRCA2 mutations were prognostic of improved PFS/OS on multivariate analysis, 
as compared to BRCA1/2 intact OC, despite the limited cohort size of 1248 patients. Reasons 
for the discrepancy in survival between BRCA1-mutated OC and BRCA1-methylated OC, 
relative to BRCA1/2 intact OC, are unclear and warrant further investigation. Compared to 
BRCA2 mutations, the survival benefit conferred by BRCA1 mutations is of a lesser magnitude, 
echoing recent reports evaluating survival in BRCA1/2-mutated OC. Some studies find no 
survival difference between BRCA1-mutated and BRCA1/2 wild type cancers15,49. A pooled 
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cohort (>6500 participants) demonstrated the expected positive prognostic effect of BRCA1 
mutation on OS, which was to a markedly lesser degree than observed with BRCA2 mutation 
(BRCA1 mutation HR 0.83, 95% CI 0.74-0.93, P<0.001; BRCA2 mutation HR 0.55, 95% CI 
0.47-0.65, P=0.002)53. It is likely the survival benefit is diluted by heterogeneity within BRCA1-
mutated disease, whereby some cases assigned a BRCA1-mutated status actually behave in 
HR proficient manner. Similarly, the difference in survival patterns between BRCA1 mutation 
and BRCA1 methylation, despite sharing similar clinicopathological features, could be explained 
in part by heterogeneity within BRCA1-methylated OC, as discussed further below. Moreover, 
methylation as a rule is a more dynamic mechanism relative to mutation, and subject to change 
depending on specific characteristics of the tumor microenvironment. The survival benefit 
observed in BRCA1/2-mutated OC results from their marked sensitivity to platinum-based 
chemotherapy, used a standard of care in the (neo)adjuvant treatment of OC. Potentially, 
chemotherapy induces changes affecting the methylation levels of the BRCA1 promoter, 
causing earlier and perhaps more frequent resistance to platinum-based chemotherapy than is 
observed in BRCA1-mutated OC. This may manifest as methylation loss in relapsed BRCA1-
methylated OC, observed in 16.7% - 80% of small mostly retrospective cohorts of 6 to 13 paired 
primary/recurrent BRCA1-methylated HGSC43,52,54,55.  
The pooled BRCA1 methylation rate was 16.3%. While this reflects most reports of BRCA1 
methylation frequency, there is marked variability in the reported occurrence of BRCA1 
methylation in OC (5%-89.9%)9,39. Amongst studies included in this meta-analysis, BRCA1 
methylation frequency ranged from 6.2% to 73.6%, with an interquartile range of 10.1% - 18.9%. 
To some extent, this could be explained by cohort sampling bias, in terms of size, populations 
and histological subtypes included, with slightly higher rates often observed when cohorts are 
restricted to HGSC (Table S2A). In breast cancer, BRCA1 methylation is more frequent 
amongst Asians, as compared to Caucasians56, however ethnicity data was not available in this 
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meta-analysis. Moreover, tissue sampling size and content introduces bias owing to variations 
in sampling sites (ovary versus metastatic), neoplastic cell content and intratumor 
heterogeneity. Four studies report particularly high BRCA1 methylation rates: 21.4%35, 33.6%16, 
42%39 and 73.7%43. This latter cohort, which confirmed all its MSP-GE determined BRCA1-
methylated OC cases with Sanger sequencing, consisted solely of relapsed cases, which may 
account to some extent for this variation. We also observed that these 4 studies determined 
BRCA1 methylation using MSP-GE, whilst studies utilising quantitative methodologies or high 
throughput microarrays reported rates varying between 8.2% and 16%. In a meta-analysis 
evaluating BRCA1 promoter methylation as a risk for the development of breast cancer, studies 
utilising MSP were significantly more likely to report higher frequencies of BRCA1 methylation56. 
Non-specific primer binding or incomplete bisulfite conversion have linked MSP with false 
positive results, and may account for this observation to some extent57.  
The marked variation in the methodology used to determine BRCA1 promoter methylation is 
also likely to contribute to differences in reported BRCA1 methylation rates (Figure S1). This 
epigenetic phenomenon is characterized by the methylation of CpG dinucleotides within a ∼2.7 
kB 5’CpG island containing 96 CpG dinucleotides and involving the bidirectional BRCA1 
promoter and its adjacent alternative first exons (exon 1a/1b)58,59. An essential regulatory area 
202 bp downstream and 20 bp upstream of the BRCA1 transcription start site at exon 1a 
(according to GenBank U37574) contains sequence specific transcription factor binding sites 
that prevent transcription when methylated60. However, the individual contribution of CpG 
dinucleotides within this area (or elsewhere in the 2.7 kb CpG island) to the regulation of 
BRCA1 transcription has yet to be comprehensively evaluated in OC. Commonly used assays 
include MRED, MSP, methylation sensitive multiplex ligation probe amplification (MS-MLPA), 
bisulfite sequencing and, more recently, GWMA. In contrast to the other methodologies, the 
latter correlates BRCA1 mRNA expression to CpG dinucleotides’ methylation status (9-46 
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assessed), to enable the selection of relevant CpG probes3,15. Despite this common rationale, 2 
studies15,42 using the same GWMA assay (Illumina Infinium HumanMethylation 450k Beadchip) 
selected 8 and 21 CpG probes to determine BRCA1 methylation status within their samples. 
Were both assays applied to the same samples, different results may ensue depending on the 
level of methylation in tumor samples at these CpG sites. PCR-based assays use different 
primers which assess often overlapping though different regions of the BRCA1 promoter, 
resulting in different CpG dinucleotides being interrogated between assays (Table S2A, Figure 
S12). One study using 2 sets of primers, each targeting a different region within the BRCA1 
promoter, reported different methylation levels within the same OC sample: 17.5% (region 1) 
and 3.3% (region 2)61. Using an arbitrary cut-off of 10% to define methylation, and had only one 
set of primers been used, this sample may or may not be defined as BRCA1-methylated. 
Moreover, methylation of individual CpG dinucleotides, which may or may not be involved in 
regulation of BRCA1 transcription, cannot be distinguished within a PCR-based assay. The 
importance of CpG site selection to determine BRCA1 methylation status was underscored in a 
study demonstrating a correlation between high methylation levels at the BRCA1 promoter and 
the triple negative breast cancer subtype, as determined by pyrosequencing. However the level 
of methylation was variable across the 11 CpG sites evaluated, with 4 CpG sites displaying 
low/lack of methylation62. Differences also exist with regards to assay interpretation, which 
includes GE (used in 8 of the included studies) or quantitative analyses. The latter use varying 
methodologies to 1) determine non-methylated reads and 2) quantify the percentage methylated 
reads within a sample. Quantitative analyses arbitrarily define low thresholds (4-10%) to define 
methylation, without critically evaluating the threshold required for BRCA1 inactivation. 
Arguably, a low threshold is selected to account for potential dilution of methylated fragments in 
specimens with low neoplastic cell content or tumor heterogeneity, though may result in 
labelling non-BRCA1-methylated samples with high neoplastic cell content/homogeneous tumor 
as BRCA1-methylated Finally, whilst technically valid, these assays have not been compared to 
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one another in the same OC dataset. A study compared methylation status of 4 genes using 
MSP-GE, quantitative MS-MLPA and quantitative multiplex MSP in 40 breast cancers, and 
found high discrepancies between MSP-GE and the quantitative assays’ results63. Methylation 
assay heterogeneity was evident between studies included in this meta-analysis. In an 
exploratory analysis, we identified a survival benefit within a subset of BRCA1-methylated OC 
identified with MSP-GE, as compared to non-BRCA1-methylated OC. This subset was 
particularly homogeneous as 5 of the 7 cohorts included13,16,35,4143 evaluated the same 7 CpG 
sites, whilst 4 CpG sites were common to 6 cohorts (CpG details for 1 cohort were unavailable). 
This Our findings may give credence to these particular CpG sites in terms of their essential role 
on BRCA1 transcription. However, only 2 of these 7 cohorts individually reported an improved 
survival for BRCA1-methylated OC, compared to non-BRCA1-methylated OC, as did 1 of 5 
eligible studies using identical PCR primers excluded from this analysis (Table S1)14,17,29,30. 
While this observation could be related to individual studies’ small sample size, our findings are 
exploratory and should be interpreted with caution.  
Factors other than diagnostic methylation assays may contribute to heterogeneity within 
BRCA1-methylated OC, as is observed in BRCA1-mutated disease. Indeed, studies suggest 
resistance to platinum and/or PARPi therapy with BRCA1 mutations occurring within the BRCA1 
RING domain64. Moreover, mono-allelic BRCA1 mutations do not display an HR-deficient 
phenotype when BRCA1-locus LOH is absent, as evaluated in a cohort of 52 BRCA1-mutated 
OC65. In this study, 7% of BRCA1-mutated OC had absent BRCA1-locus LOH and a worse 
survival, compared to BRCA1-mutated OC with BRCA1-locus LOH (P=0.02). Similarly, the 
discrepancy between preclinical findings and our analysis results with regards to platinum 
sensitivity and survival may lie in heterogeneity within BRCA1-methylated OC. This has been 
illustrated in BRCA1-methylated HGSC patient-derived xenograft models, whereby one model 
was cisplatin sensitive, and the other cisplatin resistant, using the same MSP assay51.  
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Potentially, mono-allelic BRCA1 methylation with absent BRCA1-locus LOH would result in 
transcription of an intact BRCA1 on the non-methylated allele, resulting in a functioning BRCA1 
protein. By pooling studies evaluating LOH in BRCA1-methylated OC, we found that 19.6% 
(n=18/92) of BRCA1-methylated OC have absent LOH, as determined by analyzing 
microsatellites near BRCA1 (Table S6). Current methylation assays do not routinely examine 
BRCA1 locus LOH, nor do they differentiate between mono/bi-allelic methylation. In quantitative 
assays, greater than 50% methylation at the BRCA1 promoter may assume bi-allelic 
methylation. A recent study estimated percentage BRCA1 promoter methylation (adjusted for 
BRCA1 locus LOH, neoplastic cellularity and BRCA1 copy number) to differentiate homozygous 
(>50% methylation) and heterozygous (<50% methylation) BRCA1 methylation in 21 BRCA1-
methylated tumors from the ARIEL2 phase II clinical trial. Encouragingly, homozygous BRCA1-
methylated OC (n=6) was associated with a longer PFS than BRCA1/2 intact OC (n=143), 
though this was not statistically significant (median PFS 14.5 months (95% CI 4.8-18.3 months) 
vs 5.5 months (95% CI 5-6.2 months), P=0.06)66. The development of allele-specific methylation 
methodologies that include LOH assessment, confirmed by absent/low BRCA1 mRNA 
expression, and ideally using specimens with 100% neoplastic cell content should minimize 
heterogeneity and permit a more accurate determination of BRCA1 epigenetically silenced 
tumors, or ‘true’ BRCA1-methylated OC. 
This is the most extensive meta-analysis to date evaluating the clinical characteristics of 
BRCA1-methylation in OC. The inclusion of published and unpublished studies without 
publication language restrictions, along with the use of IPD from studies assessed to be of 
overall good quality further strengthens our results. Limitations include 1) incomplete inclusion 
of all eligible studies identified through our search strategy, 2) statistically significant 
heterogeneity between cohorts in the assessment of PFS and OS, which was mitigated by the 
use of a mixed effect model, 3) heterogeneity in the methylation assays utilised between 
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included studies, 4) availability of BRCA1/2 mutation status, which enables a more thorough 
assessment of the prognostic effect of BRCA1 methylation on survival by using BRCA1/2 intact 
OC as a comparator, was limited to n=1248/2636 patients. 
 
CONCLUSION 
In the largest meta-analysis on this topic, we show that BRCA1-methylated OC has a clinico-
pathological profile similar to that of BRCA1-mutated OC, presenting at a younger age as 
advanced stage HGSC. However, BRCA1 methylation does not predict for platinum sensitivity 
nor is it prognostic of survival. While early and/or frequent platinum resistance mechanisms may 
account for this observation, there is significant heterogeneity between methylation assays used 
to detect BRCA1-methylated OC, in terms of the exact CpG sites assessed and the 
interpretation of the observed result. Moreover, these assays are not allele-specific and do not 
account for BRCA1-locus LOH. Potentially, a comprehensive assay that examines CpG 
dinucleotides critical to BRCA1 transcription in OC specimens in an allele-specific manner, 
combined with assessment of BRCA1-locus LOH may permit a better selection of ‘true’ BRCA1-
methylated OC. Defined as such, BRCA1-methylated OC may represent a smaller subset, yet 
permit a more accurate selection of patients with OC that would derive clear benefit from PARPi 
and other novel therapies targeting HR-deficient OC. 
FUNDING 
This work was supported in part by the North East Cancer Research and Education Trust (no 





The study funders had no role in in the design of the study; the collection, analysis, or 
interpretation of the data; the writing of the manuscript; and the decision to submit the 
manuscript for publication.  
The results shown in this meta-analysis are in part based upon data generated by the Cancer 
Genome Atlas (TCGA) Research Network (https://www.cancer.gov/tcga) and the Australian 
Ovarian Cancer Study Group (https://www.aocstudy.org).  
As outlined on the TCGA website (https://www.cancer.gov/about-
nci/organization/ccg/research/structural-genomics/tcga/using-tcga/citing-tcga), authors are 
permitted to use data from TCGA once the TCGA Research Network is acknowledged, as 
above, in their work. 
The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research 
and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland 
Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The 
Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State 
Applications 191, 211 and 182) and the National Health and Medical Research Council of 
Australia (NHMRC; ID400413 and ID400281). The Australian Ovarian Cancer Study gratefully 
acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), 
Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges 
the cooperation of the participating institutions in Australia and acknowledges the contribution of 
the study nurses, research assistants and all clinical and scientific collaborators to the study. The 
complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all of 
the women who participated in these research programs. 
DISCLOSURES   
26 
 
RK has received conference travel reimbursement from Astra Zeneca, outside the submitted 
work. EB has received travel and advisory board fees from Roche Pharma, Tesaro, Incyte; 
travel and congress fees from Astra Zeneca; advisory board fees from Clovis, Seattle Genetics, 
Amgen; and institution funding from Roche Pharma, all outside the submitted work. JS has 
received honoraria, consulting/advisory fees,  travel fees and institutional research funding from 
Astra Zeneca, Clovis, PharmaMar, Pfizer, TESARO, MSD, as well as institutional research 
funding from Merck, Bayer; consulting/advisory fees from Lilly, Roche; honoraria from Eisai, 
Olympus, Johnson and Johnson, TEVA; travel fees from Roche. GM has had a consultant role 
or participated on scientific advisory boards of Astra Zeneca, Chrysalis, ImmunoMET, Ionis, 
Mills Institute for Personalized Care (MIPCC), PDX Pharma, Signalchem Lifesciences, 
Symphogen, Tarveda. GM has stock or options in Catena Pharmaceuticals, ImmunoMet, 
SignalChem, Spindletop Ventures, Tarveda, and has received research funding from Astra 
Zeneca, Ionis, Karus Therapeutics, Nanostring, Pfizer, Takeda/Millenium Pharmaceuticals. KT 
is an employee of and may have stocks in Myriad Genetics. DB has received research funding 
and clinical trial support from Genentech/Roche, Astra Zeneca, and Beigene. LW has received 
research support, honoraria or travel reimbursement from TESARO, medac oncol, GSK, MSD, 









1. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nature reviews 
Cancer. 2010;10(11):803-808. 
2. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clinical 
cancer research : an official journal of the American Association for Cancer Research. 
2007;13(24):7421-7431. 
3. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615. 
4. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand 
the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian 
cancer. J Clin Oncol. 2010;28(22):3570-3576. 
5. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with 
platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of 
outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-
861. 
6. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict 
homologous recombination repair defects in epithelial ovarian cancer. British journal of cancer. 
2012;107(10):1776-1782. 
7. Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian 
carcinoma: a population-based study. Cancer research. 2000;60(19):5329-5333. 
8. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian 
cancer. Journal of the National Cancer Institute. 2002;94(1):61-67. 
9. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic 
breast and ovarian cancer: correlation with disease characteristics. Oncogene. 
1999;18(11):1957-1965. 
10. Pradjatmo H, Dasuki D, Anwar M, Mubarika S, Harijadi. Methylation status and 
immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pacific journal of cancer 
prevention : APJCP. 2014;15(21):9479-9485. 
11. Stordal B, Timms K, Farrelly A, et al. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals 
only one functionally deleterious BRCA1 mutation. Molecular oncology. 2013;7(3):567-579. 
12. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss 
have distinct molecular abnormalities. BMC cancer. 2008;8:17. 
13. Swisher EM, Gonzalez RM, Taniguchi T, et al. Methylation and protein expression of DNA repair 
genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal 
carcinomas. Molecular cancer. 2009;8:48. 
14. Wang C, Horiuchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and 
malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the 
BRCA1 gene. The Journal of pathology. 2004;202(2):215-223. 
15. Cunningham JM, Cicek MS, Larson NB, et al. Clinical characteristics of ovarian cancer classified 
by BRCA1, BRCA2, and RAD51C status. Scientific reports. 2014;4:4026. 
16. Ignatov T, Eggemann H, Costa SD, Roessner A, Kalinski T, Ignatov A. BRCA1 promoter 
methylation is a marker of better response to platinum-taxane-based therapy in sporadic 
epithelial ovarian cancer. Journal of cancer research and clinical oncology. 2014;140(9):1457-
1463. 
17. Bai X, Fu Y, Xue H, et al. promoter hypermethylation in sporadic epithelial ovarian carcinoma: 
Association with low expression of BRCA1, improved survival and co-expression of DNA 
methyltransferases. Oncology letters. 2014;7(4):1088-1096. 
18. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian 
cancer prognosis. Gynecologic oncology. 2006;101(3):403-410. 
28 
 
19. Prat J, Oncology FCoG. FIGO's staging classification for cancer of the ovary, fallopian tube, and 
peritoneum: abridged republication. Journal of gynecologic oncology. 2015;26(2):87-89. 
20. Timms KM, Abkevich V, Hughes E, et al. Association of BRCA1/2 defects with genomic scores 
predictive of DNA damage repair deficiency among breast cancer subtypes. Breast cancer 
research : BCR. 2014;16(6):475. 
21. Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts 
Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative 
Breast Cancer. Clinical cancer research : an official journal of the American Association for 
Cancer Research. 2016;22(15):3764-3773. 
22. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-
randomised studies of interventions. BMJ (Clinical research ed). 2016;355:i4919. 
23. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: 
Springer; 2000. 
24. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B. survcomp: an R/Bioconductor package 
for performance assessment and comparison of survival models. Bioinformatics. 
2011;27(22):3206-3208. 
25. Therneau TM, Grambsch PM, Pankratz VS. Penalized Survival Models and Frailty. Journal of 
Computational and Graphical Statistics. 2003;12(1):156-175. 
26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 
1995;57(1):289-300. 
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 
(Clinical research ed). 2003;327(7414):557-560. 
28. Deeks JJ HJ, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: 
Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, ed. Cochrane Handbook for 
Systematic Reviews of Interventions version 6.0: Cochrane; 2019. 
29. Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS. Failure of BRCA1 dysfunction to 
alter ovarian cancer survival. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2002;8(5):1196-1202. 
30. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation profiles in 
gynecological cancers and correlation with clinico-pathological data. BMC cancer. 2006;6:212. 
31. Stefansson OA, Villanueva A, Vidal A, Marti L, Esteller M. BRCA1 epigenetic inactivation predicts 
sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 
2012;7(11):1225-1229. 
32. Bernards SS, Pennington KP, Harrell MI, et al. Clinical characteristics and outcomes of patients 
with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecologic oncology. 
2018;148(2):281-285. 
33. Yates MS TK, Daniels MS, Oakley HD, Munsell MF, Lanchbury JS, Lu KH. Evaluation of BRCA1/2 
and Homologous Recombination Defects in Ovarian Cancer and Impact on Clinical Outcomes. J 
Clin Oncol 2017;35((suppl; abstr 5511)). 
34. Wang ZC, Birkbak NJ, Culhane AC, et al. Profiles of genomic instability in high-grade serous 
ovarian cancer predict treatment outcome. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2012;18(20):5806-5815. 
35. Wiley A, Katsaros D, Chen H, et al. Aberrant promoter methylation of multiple genes in 
malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 
2006;107(2):299-308. 
36. Rzepecka IK, Szafron L, Stys A, et al. High frequency of allelic loss at the BRCA1 locus in ovarian 
cancers: clinicopathologic and molecular associations. Cancer genetics. 2012;205(3):94-100. 
29 
 
37. Montavon C, Gloss BS, Warton K, et al. Prognostic and diagnostic significance of DNA 
methylation patterns in high grade serous ovarian cancer. Gynecologic oncology. 
2012;124(3):582-588. 
38. Ruscito I, Dimitrova D, Vasconcelos I, et al. BRCA1 gene promoter methylation status in high-
grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and 
ovarian cancer diagnosis consortium (OVCAD). European journal of cancer (Oxford, England : 
1990). 2014;50(12):2090-2098. 
39. Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of 
response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer 
investigation. 2009;27(8):877-884. 
40. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 
abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. 
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, 
Inc. 2012;25(5):740-750. 
41. Radosa MP, Hafner N, Camara O, et al. Loss of BRCA1 protein expression as indicator of the 
BRCAness phenotype is associated with favorable overall survival after complete resection of 
sporadic ovarian cancer. International journal of gynecological cancer : official journal of the 
International Gynecological Cancer Society. 2011;21(8):1399-1406. 
42. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of 
chemoresistant ovarian cancer. Nature. 2015;521(7553):489-494. 
43. Prieske K, Prieske S, Joosse SA, et al. Loss of BRCA1 promotor hypermethylation in recurrent 
high-grade ovarian cancer. Oncotarget. 2017;8(47):83063-83074. 
44. Teixeira LA, Candido dos Reis FJ. BRCA1 Expression by Immunohistochemistry and Prognosis in 
Ovarian Cancer: A Systematic Review and Meta-Analysis. Targeted Oncology. 2020;15(1):37-46. 
45. Gras E, Cortes J, Diez O, et al. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 
mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. 
Cancer. 2001;92(4):787-795. 
46. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of 
BRCA1 and BRCA2 in ovarian cancer. Journal of the National Cancer Institute. 2002;94(18):1396-
1406. 
47. Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E, van Diest PJ. Methylation profiles of 
hereditary and sporadic ovarian cancer. Histopathology. 2010;57(3):363-370. 
48. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE. BRCA2 alteration 
is important in clear cell carcinoma of the ovary. Clinical genetics. 2009;76(2):161-167. 
49. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, 
chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Jama. 
2011;306(14):1557-1565. 
50. Veeck J, Ropero S, Setien F, et al. BRCA1 CpG island hypermethylation predicts sensitivity to 
poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010;28(29):e563-564; 
author reply e565-566. 
51. Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-
grade serous ovarian cancer patient-derived xenografts. Molecular oncology. 2014;8(3):656-668. 
52. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian 
carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. The Lancet 
Oncology. 2017;18(1):75-87. 
53. Candido-dos-Reis FJ, Song H, Goode EL, et al. Germline mutation in BRCA1 or BRCA2 and ten-
year survival for women diagnosed with epithelial ovarian cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2015;21(3):652-657. 
30 
 
54. Patel JN, Braicu I, Timms KM, et al. Characterisation of homologous recombination deficiency in 
paired primary and recurrent high-grade serous ovarian cancer. British journal of cancer. 
2018;119(9):1060-1066. 
55. Bisogna M, Dao F, Olvera N, Bacares R, Zhang L, Levine DA. Abstract A05: BRCA1 promoter 
hypermethylation loss in recurrent high-grade serous carcinoma. Clinical Cancer Research. 
2016;22:A05-A05. 
56. Zhang L, Long X. Association of BRCA1 promoter methylation with sporadic breast cancers: 
Evidence from 40 studies. Scientific reports. 2015;5:17869. 
57. Lan VT, Ha NT, Uyen NQ, et al. Standardization of the methylation‑specific PCR method for 
analyzing BRCA1 and ER methylation. Molecular medicine reports. 2014;9(5):1844-1850. 
58. Brown MA, Xu CF, Nicolai H, et al. The 5' end of the BRCA1 gene lies within a duplicated region 
of human chromosome 17q21. Oncogene. 1996;12(12):2507-2513. 
59. Xu CF, Chambers JA, Solomon E. Complex regulation of the BRCA1 gene. The Journal of biological 
chemistry. 1997;272(34):20994-20997. 
60. Thakur S, Croce CM. Positive regulation of the BRCA1 promoter. The Journal of biological 
chemistry. 1999;274(13):8837-8843. 
61. Franzese E, Centonze S, Diana A, et al. Genomic Profile and BRCA-1 Promoter Methylation Status 
in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. 
Frontiers in oncology. 2019;9:1289. 
62. Daniels SL, Burghel GJ, Chambers P, et al. Levels of DNA Methylation Vary at CpG Sites across the 
BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood 
and Tumour DNA. PloS one. 2016;11(7):e0160174. 
63. Suijkerbuijk KP, Pan X, van der Wall E, van Diest PJ, Vooijs M. Comparison of different promoter 
methylation assays in breast cancer. Analytical cellular pathology (Amsterdam). 2010;33(3):133-
141. 
64. Dimitrova D, Ruscito I, Olek S, et al. Germline mutations of BRCA1 gene exon 11 are not 
associated with platinum response neither with survival advantage in patients with primary 
ovarian cancer: understanding the clinical importance of one of the biggest human exons. A 
study of the Tumor Bank Ovarian Cancer (TOC) Consortium. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine. 2016;37(9):12329-12337. 
65. Maxwell KN, Wubbenhorst B, Wenz BM, et al. BRCA locus-specific loss of heterozygosity in 
germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8(1):319. 
66. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the 








Table 1. Association between BRCA1 methylation status and clinico-pathological factors  
31 
 






Non-BRCA1 methylated  
(n=2206) 
Adjusted p-value 
Age, No. (%)   0.005 
<59 245 (57%) 1090 (49.6%)  
≥59 185 (43%) 1109(50.4%)  
Missing 0 7  
Grade, No (%)   0.03 
Low 25 (6%) 198 (9.1%)  
High 389 (94%) 1979 (90.9%)  
Missing 16 29  
FIGO stage, No (%)   0.47 
I/II 48 (11.2%) 339 (15.4%)  
III/IV 381 (88.8%) 1862 (84.6%)  
Missing 1 5  
Histology, No (%)   0.97 
Serous 354 (82.3%) 1799 (81.6%)  
Non-serous 76 (17.7%) 407 (18.4%)  
Missing 0 0  
Residual disease post 
cytoreduction, No (%) 
  0.47 
Macro <1cm 306 (73.6%) 1451 (71.5%)  
Macro ≥1cm 110 (26.4%) 577 (28.5%)  
Missing 14 178  
Platinum sensitivity, No 
(%) 
  0.34 
<6 months 66 (19.4%) 463 (28.2%)  


















Table 2. Univariate and multivariate analysis for PFS and OS according to BRCA1/2 aberrations 
(Using a mixed effects model adjusting for cohort) 
 
 Hazard ratio (95% CI); p value 
 Univariate analysis Multivariate analysis* 
Entire cohort 
(n=2636) PFS OS PFS OS 
Age - - 1.10 (1.00 – 1.25); p=0.05 
1.22 (1.10 – 1.37); 
p=0.0003 
Grade - - 2.38 (1.84 – 3.07); p<0.0001 
1.80 (1.35 – 2.41); 
p<0.0001 
Stage - - 2.89 (2.36 – 3.47); p<0.0001 
2.76 (2.19 – 3.48); 
p<0.0001 
Residual 
disease - - 
1.59 (1.41 – 1.80); 
p<0.0001 




1.01 (0.87 – 1.16); 
p=0.98 
1.02 (0.87 – 1.18); 
p=0.96 
1.01 (0.88 – 1.15); 
p=0.92 







PFS OS PFS OS 
Age - - 1.08 (0.93 – 1.25); p=0.33 
1.18 (1.00 – 1.37); 
p=0.04 
Grade - - 2.30 (1.48 – 3.57); p<0.001 
1.97 (1.19 – 3.27); 
p=0.01 
Stage - - 4.07 (3.00 – 5.52); p<0.001 
3.10 (2.18 – 4.42); 
p<0.001 
Residual 
disease - - 
1.37 (1.15 – 1.62); 
p<0.001 








1.06 (0.85 – 1.34); 
p=0.59 








0.78 (0.62 – 0.99); 
p=0.04 






0.57 (0.41-0.80);   
p<0.001 
0.51 (0.37 – 0.69); 
p<0.001 
0.51 (0.35 – 0.73); 
p<0.001 
*All clinical variables within the multivariate model are binary, as follows: Age: 0 for <60 (median age) and 
1 for ≥60; Grade: 0 for low grade, 1 for high grade; 0 for Stage I/II, 1 for Stage III/IV; Residual disease: 0 







Table 3. Association of BRCA1 methylation with PFS and OS according to methylation assay 
subgroup 
MRED: methylation-sensitive restriction endonuclease digest; MSP: methylation-specific PCR; PFS: progression-free 
survival; OS: overall survival 
 
 BRCA1 methylation Hazard Ratio (95%CI); p value 
(methylated relative to non-methylated) 
Univariable PFS OS 
Genome wide methylation array 
correlated to BRCA1 mRNA 
expression 
1.12 (0.89 – 1.41), p=0.33 
(n=976, 767 events) 
1.09 (0.85 – 1.39), p =0.51 
(n=1043, 690 events) 
MRED or MSP with quantitative 
analysis 
1.47 (1.10 – 1.96), p =0.008 
(n=781, 590 events) 
1.45 (1.05 – 2.00), p =0.02 
(n=826, 382 events) 
MSP with gel electrophoresis 
0.80 (0. 66 – 0.97), p =0.02 
(n=706, 518 events) 
0.80 (0.63 – 1.00), p =0.05 
(n=730, 411 events) 
Multivariable* PFS OS 
Genome wide methylation array 
correlated to BRCA1 mRNA 
expression 
1.11 (0.87 – 1.42), p =0.40 
(n=838, 657 events) 
1.04 (0.80 – 1.35), p =0.78 
(n=896, 591 events) 
MRED or MSP with quantitative 
analysis 
1.36 (1.00 – 1.84), p =0.04 
(n=733, 556 events) 
1.40 (1.01 – 1.94), p =0.04 
(n=774, 354 events) 
MSP with gel electrophoresis 
0.82 (0.68 – 1.00), p =0.05 
(n=655, 482 events) 
0.81 (0.64 – 1.03), p =0.08 
(n=724, 407 events) 
*Adjusted for binary clinical variables as follows: Age: 0 for <60 (median age) and 1 for ≥60; Grade: 0 for low grade, 1 









Figure 1. Flow chart of study 
Figure 2. HRD score as assessed on 447 tumor samples obtained from the TCGA 2011 
and MDACC 2010 cohorts, according to underlying BRCA1/2 aberration 
Box plots depict the median and 95% confidence intervals of the HRD scores according to the underlying BRCA1/2 
aberration in the TCGA 2011 and MDACC 2010 cohorts. The dotted line represents the threshold value of 42 above 
which samples are considered to be homologous recombination deficient as per the HRD score assay. Stars depict 
the level of statistical significance between sets of groups (unpaired t-tests). Numbers in each subgroup are as 
follows: Wild type – n=286; BRCA1 methylation – n=65; BRCA1 mutation – n=57; BRCA2 mutation – n=39. 
 
Figure 3. Univariate and multivariate analyses of BRCA1 methylation on progression-free 
survival (PFS) and overall survival (OS) by study and for the combined dataset 
A: Univariate analyses; B: Multivariate analyses whereby hazard ratios (HR) are derived from a cox proportional 
hazards model adjusted for binary clinical variables as follows: age: 0 for <60 (median age) and 1 for ≥60; Grade: 0 
for low grade, 1 for high grade; 0 for Stage I/II, 1 for Stage III/IV; Residual disease: 0 for < 1cm, 1 for ≥1cm. Pooled 
analyses performed using a mixed effect model adjusting for cohort. Numbers in ‘non-BRCA1-methylated’ and 
‘BRCA1-methylated’columns represent number of events/total numbers. CI = confidence interval.  
Figure 4. Survival in the entire pooled dataset and a pooled subset with known BRCA1/2 
mutation status 
Kaplan Meier curves depicting progression-free and overall survival in (A) the entire pooled cohort (n=2636) and (B) a 
pooled subset of the entire cohort with known BRCA1/2 mutation status (n=1248). (A) BRCA1 methylation (orange) 
and no BRCA1 methylation (grey) curves are depicted. Univariate hazard ratios (HR), 95% confidence interval (CI) 
and p value (Log rank test) for BRCA1 methylation vs no BRCA1 methylation, adjusted for study, are given (B) 
BRCA1 methylation (orange), BRCA1 mutation (dark blue), BRCA2 mutation (light blue) and BRCA1/2 intact (non-
BRCA1-methylated BRCA1/2 wild type) (grey) curves are depicted. Univariate hazard ratios, 95% confidence interval 
(CI) and p value (Log rank test) for BRCA1 methylation vs BRCA1/2 intact, adjusted for study, are given. 
 
Figure 5. Survival analyses in subgroups combined according to methylation assay 
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Kaplan Meier curves depicting progression-free and overall survival in subgroups combined according to methylation 
assay. Univariate hazard ratios (HR) and 95% confidence interval (CI) and p value (Log rank test) for BRCA1 
methylation (orange), as compared to no BRCA1-methylation (grey), adjusted for cohort, are given.  
MRED = methylation-sensitive restriction endonuclease digestion, MSP = methylation specific PCR; CI = confidence 
interval; BRCA1 meth = BRCA1 methylation; non-BRCA1-meth=no BRCA1 methylation 
 
 
